bs-82923C
[Life Science]
NLG919
www.biossusa.com
support@biossusa.com
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
support@biossusa.com
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET
Formulation White solid
Storage: -20°C
Product Information:
NLG919 (1402836-58-1) is a potent IDO-pathway inhibitor (Ki = 7nM; EC50 = 75nM).1 It synergizes with chemo-radiation therapy to promote T cell dependent complement deposition in a murine model of glioblastoma.2 In combination with paclitaxel in a mouse B16-F10 melanoma model, NLG919 increased the percentage of CD3+, CD8+, and CD4+ T cells and secretion of IFN-γ and interleukin-2 while decreasing the percentage of CD4+CD25+ regulatory T cells.3
Description:
CAS Number: 1402836-58-1<br></br>Chemical Name: 1-Cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol<br></br>Molecular weight: 282.39<br></br>Formula: C18H22N2O<br></br>Solubility: DMSO (10 mg/ml)<br></br>Physical Properties: White solid<br></br>Purity: 985 by TLC, NMR (Conforms)
Size: 5mg, 25mg
Applications: Life Science
For research use only. Not intended for diagnostic or therapeutic use.